1. Executive Summary
2. The Global Burden of Cancer
2.1 The Impact of Cancer
2.2 Incidence: Which Cancers Are The Most Commonly Diagnosed?
2.3 Mortality: Which Cancers Kill the Most People?
2.3.1 The Developed World
2.3.2 The Developing World
3. The Physiology of Cancer and the Pharmacology of Treatments
3.1 Uncontrolled Growth
3.1.1 Oncogenes and Tumour Suppressor Genes
3.1.2 Immortality
3.1.3 Apoptosis
3.1.4 Angiogenesis
3.1.5 Dedifferentiation
3.1.6 Invasiveness and Metastasis
3.2 Treating Tumours
3.3 Chemotherapy
3.4 Traditional Antineoplastics
3.4.1 Alkylating Agents
3.4.1.1 Traditional Alkylating Agents
3.4.1.2 Platinum Compounds
3.4.2 Antimetabolites
3.4.3 Plant Derivatives
3.4.4 Cytotoxic Antibiotics
3.4.5 Adjuvant Therapies
3.5 Novel Antineoplastics
3.5.1 Monoclonal Antibodies
3.5.2 Kinase Receptor Antagonists
3.5.3 Other Novel Antineoplastics
3.6 Hormone Therapies
3.7 Immunotherapies
4. The Global Cancer Drug Market, 2010-2025
4.1 The Scope of this Report
4.1.1 Drugs Excluded from this Report
4.2 The Worldwide Oncology Market
4.3 Oncology Revenues by Geographical Area
4.4 Leading Markets and Emerging Markets
4.4.1 The Seven Leading Markets
4.4.2 The Five Emerging Markets
4.5 Oncology Market Break-Down by Category
4.5.1 Oncology Market Break-Down by Mechanism of Action
4.6 Oncology Market Sales Forecast, 2010-2025
4.7 Traditional Antineoplastics
4.7.1 Sales Forecast for Traditional Antineoplastics, 2010-2025
4.8 Novel Antineoplastics
4.8.1 Sales Forecast for Novel Antineoplastics, 2010-2025
4.9 Hormone Therapies
4.9.1 Sales Forecast for Hormone Therapies, 2010-2025
4.10 Immunotherapies
4.10.1 Sales Forecast for Immunotherapy Market, 2010-2025
4.11 How Market Shares of Each Category will Change, 2010-2025
5. The Market Leaders: Top Ten Anti-Cancer Drugs
5.1 The Costs of The Top Ten Drugs
5.2 Important Notes on the Top Ten Drugs
5.3 Avastin (bevacizumab) - Roche
5.3.1 Overview
5.3.2 Recent Performance
5.3.3 Forecast
5.3.4 Comment
5.4 MabThera (rituxamab) – Roche
5.4.1 Overview
5.4.2 Recent Performance
5.4.3 Forecast
5.4.4 Comment
5.5 Herceptin (trastuzumab) - Roche
5.5.1 Overview
5.5.2 Recent Performance
5.5.3 Forecast
5.5.4 Comment
5.6 Glivec/Gleevec (imatinib) - Novartis
5.6.1 Overview
5.6.2 Recent Performance
5.6.3 Forecast
5.6.4 Comment
5.7 Taxotere (docetaxel) - Sanofi-Aventis
5.7.1 Overview
5.7.2 Recent Performance
5.7.3 Forecast
5.7.4 Comment
5.8 Eloxatin (oxaliplatin) - Sanofi-Aventis
5.8.1 Overview
5.8.2 Recent Performance
5.8.3 Forecast
5.8.4 Comment
5.9 Arimidex (anastrazole) - AstraZeneca
5.9.1 Overview
5.9.2 Recent Performance
5.9.3 Forecast
5.9.4 Comment
5.10 Gemzar (gemcitabine) - Eli Lilly
5.10.1 Overview
5.10.2 Recent Performance
5.10.3 Forecast
5.10.4 Comment
5.11 Erbitux (cetuximab) - Eli Lilly/BMS/Merck KGaA
5.11.1 Overview
5.11.2 Recent Performance
5.11.3 Forecast
5.11.4 Comment
5.12 Alimta (pemetrexed) - Eli Lilly
5.12.1 Overview
5.12.2 Recent Performance
5.12.3 Forecast
5.12.4 Comment
6. The Market Leaders: The Top Five Companies
6.1 Roche
6.1.1 Key Oncology Products
6.1.2 Pipeline
6.1.3 Comment
6.2 Novartis
6.2.1 Key Oncology Products
6.2.2 Pipeline
6.3 Sanofi-Aventis
6.3.1 Key Oncology Products
6.3.2 Pipeline
6.3.3 Comment
6.4 AstraZeneca
6.4.1 Key Oncology Products
6.4.2 Pipeline
6.4.3 Comment
6.5 Eli Lilly
6.5.1 Key Oncology Products
6.5.2 Pipeline
6.5.3 Comment
7. Major Issues Shaping the Oncology Drugs Market
7.1 SWOT Analysis of the Oncology Market, 2010-2025
7.2 The Main Factors Driving the Growth of the Oncology Market
7.2.1 High Profile
7.2.2 The Price of Drugs
7.2.3 Patient Power
7.2.4 Incremental Improvements in Treatment in the Absence of a Complete Cure
7.2.5 Effect of Generics
7.2.6 Drug Development
7.2.7 Live Licensing
7.2.8 Increase in Cancer Incidence
7.2.8.1 Aging Populations
7.2.8.2 Smoking
7.2.8.3 Dietary Trends in Industrialised Nations
7.2.8.4 Obesity
7.2.9 The Developing World
7.2.9.1 Industrialisation
7.2.9.2 The Emerging Middle Class
7.2.9.3 Diseases of Affluence
7.2.9.4 Prioritisation by Individuals
7.2.9.5 Informed Populations
7.2.9.6 Prioritisation by Governments
7.2.10 Screening and Diagnosis
7.2.11 Understanding Cancer Physiology
7.2.12 Personalised Medicine
7.2.13 Drug Delivery Systems
7.2.14 Nanotechnology
7.2.14.1 Diagnostics
7.2.14.2 Drug Delivery
7.2.14.3 Surgery
7.2.15 Off-Label Prescriptions
7.3 The Main Factors Restraining the Growth of the Oncology Market
7.3.1 The Cost-Effectiveness Debate
7.3.2 Governmental Payers and the Maximum Cost of Drugs
7.3.2.1 Healthcare Reform in the US
7.3.2.2 The Implications of Price-Capping Cancer Drugs
7.3.2.3 A Two-Tier System?
7.3.3 Pricing-Out the Developing World?
7.3.4 Risk Sharing
7.3.5 Research Bias and 'Me-Too' Drugs?
7.3.6 Public Health Initiatives
7.3.7 Efficacy, Toxicity and Alternative Treatments
7.3.8 The Patent Cliff
7.4 Unmet Needs in the Oncology Market
7.4.1 Tolerable Drugs
7.4.2 Convenient Drugs
7.4.3 Shift in Perceptions for the Goal of Cancer Treatment
7.4.4 Tumour Resistance
7.4.5 Greater Use of Pharmacogenomics
7.4.6 A Comprehensive Database of Biomarkers
7.4.7 Rigorous Endpoints in Clinical Trials
7.4.8 Is There a Research Bias?
7.4.9 Early Detection
7.4.10 Over-Treatment and Active Surveillance
7.4.11 Access to Treatment in Developing Nations
8. Interviews with Relevant Experts
8.1 Dr Hilmar Warenius
8.1.1 Current Work
8.1.2 Heterogeneity of Tumours
8.1.3 Normal Gene Products
8.1.4 Diagnostics and Pharmacogenomics
8.1.5 The Efficacy of New Treatments
8.1.6 Targeted Antineoplastics and Traditional Chemotherapy
8.1.7 Vaccines and Screening
8.1.8 Therapeutic Vaccines
8.1.9 Conclusions
8.2 Dr Howard McLeod
8.2.1 The Importance of Pharmacogenomics
8.2.2 Drivers
8.2.3 Restraints
8.2.4 Effective Drugs Missed by Clinical Trials
8.2.5 Major Breakthroughs
8.2.6 One Size Fits All?
8.2.7 Blood Tests
8.2.8 Ethics
8.3 Dr Lawrence Tamarkin
8.3.1 Impact of Nanotechnology on Oncology
8.3.1.1 Cancer as a Lifetime Chronic Condition
8.3.1.2 The Developing World
8.3.2 Timeframes
8.3.3 Difficulties and Limits
8.3.4 Further Applications
8.3.5 Drivers
8.3.6 Public Relations
9. Conclusions
9.1 Cancer Will Become an Even More Important Healthcare Priority, Especially in the Developing World
9.2 Of the Wide Range of Oncology Treatments Available, Novel Therapies are Most Important
9.3 The Global Oncology Market Will Continue to Achieve Strong Growth
9.4 The US Oncology Market Leads
9.5 In Terms of Revenue, Monoclonal Antibodies Dominate the Oncology Market
9.6 The Top Ten Drugs Owe Their Successes to Different Factors
9.7 Will Roche Continue to Lead the Global Anti-Cancer Drugs Market?
9.8 The Most Important Drivers of the Oncology Market
9.9 The Greatest Restraint on the Oncology Market
9.10 The Greatest Unmet Need in Cancer Treatment and Concluding Remarks
List of Tables
Table 2.1 Leading Causes of Death Worldwide, 2008
Table 2.2 Cancer Incidence and Mortality, 2008-2025
Table 2.3 The Ten Most Common Cancers by Incidence, 2008
Table 2.4 Five-Year Survival Rates of Nine Cancers in the UK
Table 3.1 Categories of Oncology Drug, 2010
Table 3.2 Common Side-Effects of Traditional Antineoplastic Chemotherapy
Table 4.1 Global Pharmaceutical Sales by Disease Area, 2009
Table 4.2 Oncology Drug Sales by Region, 2009
Table 4.3 Comparison of the Oncology Revenues of the Seven Leading Markets and Five Emerging Markets, 2009
Table 4.4 Comparison of the Oncology Revenues of the US, Six Other Leading Markets and Five Emerging Market Groups, 2009
Table 4.5 The Seven Leading National Markets: Oncology Sales, 2009
Table 4.6 The Five Emerging Markets: Oncology Sales, 2009
Table 4.7 Oncology Market by Therapy Type: World Sales, 2009
Table 4.8 Oncology Market Break-Down by Mechanism of Action: World Sales and Market Shares, 2009
Table 4.9 Oncology Drug Market: World Sales Forecast, 2010-2025
Table 4.10 Oncology R&D Pipelines by Category, 2009
Table 4.11 Traditional Antineoplastics: World Sales and Market Shares by Category, 2009
Table 4.12 Traditional Antineoplastics Market: World Sales Forecast, 2010-2025
Table 4.13 Novel Antineoplastics Market Categories: World Sales and Market Shares, 2009
Table 4.14 Novel Antineoplastics Market: World Sales Forecast, 2010-2025
Table 4.15 Hormone Therapy Subtypes: World Sales and Market Shares, 2009
Table 4.16 Hormone Therapy Market: World Sales Forecast, 2010-2025
Table 4.17 Immunotherapy Subtypes: World Sales, 2009
Table 4.18 Immunotherapy Market: World Sales Forecast, 2010-2025
Table 4.19 Overall Categories: Market Shares, 2010-2025
Table 5.1 The Top Ten Oncology Drugs Ranked by Total World Sales, 2009
Table 5.2 Costs of the Top Ten Anti-Cancer Drugs in the UK, 2009
Table 5.3 Avastin Sales Information, 2009
Table 5.4 Avastin Approvals, 2009
Table 5.5 Potential Indications for Avastin, 2009
Table 5.6 Avastin World Sales, 2005-2009
Table 5.7 Avastin World Sales Forecast, 2010-2025
Table 5.8 SWOT Analysis for Avastin, 2010
Table 5.9 MabThera Sales Information, 2009
Table 5.10 MabThera Approvals, 2009
Table 5.11 MabThera World Sales 2005-2009
Table 5.12 MabThera World Sales Forecast, 2010-2025
Table 5.13 SWOT Analysis for MabThera, 2010
Table 5.14 Herceptin Sales Information, 2009
Table 5.15 Potential Indications for Herceptin, 2009
Table 5.16 Herceptin World Sales, 2005-2009
Table 5.17 Herceptin World Sales Forecast, 2010-2025
Table 5.18 SWOT Analysis for Herceptin, 2010
Table 5.19 Glivec/Gleevec Sales Information, 2009
Table 5.20 Glivec/Gleevec Approvals, 2009
Table 5.21 Glivec/Gleevec World Sales, 2005-2009
Table 5.22 Glivec/Gleevec World Sales Forecast, 2010-2025
Table 5.23 SWOT Analysis for Glivec/Gleevec, 2010
Table 5.24 Taxotere Sales Information, 2009
Table 5.25 Taxotere Approvals, 2009
Table 5.26 Taxotere World Sales, 2005-2009
Table 5.27 Taxotere World Sales Forecast, 2010-2025
Table 5.28 SWOT Analysis for Taxotere, 2010
Table 5.29 Eloxatin Sales Information, 2009
Table 5.30 Eloxatin World Sales, 2005-2009
Table 5.31 Eloxatin World Sales Forecast, 2010-2025
Table 5.32 SWOT Analysis for Eloxatin, 2010
Table 5.33 Arimidex Sales Information, 2009
Table 5.34 Arimidex World Sales, 2005-2009
Table 5.35 Arimidex World Sales Forecast, 2010-2025
Table 5.36 SWOT Analysis for Arimidex, 2010
Table 5.37 Gemzar Sales Information, 2009
Table 5.38 Gemzar Approvals, 2009
Table 5.39 Potential Indications for Gemzar, 2009
Table 5.40 Gemzar World Sales, 2005-2009
Table 5.41 Gemzar World Sales Forecast, 2010-2025
Table 5.42 SWOT Analysis for Gemzar, 2010
Table 5.43 Erbitux Sales Information, 2009
Table 5.44 Marketing of Erbitux: Revenue Split, 2009
Table 5.45 Erbitux Approvals, 2009
Table 5.46 Potential Indications for Erbitux, 2009
Table 5.47 Erbitux World Sales, 2005-2009
Table 5.48 Erbitux World Sales Forecast, 2010-2025
Table 5.49 SWOT Analysis for Erbitux, 2010
Table 5.50 Alimta Sales Information, 2009
Table 5.51 Alimta Approvals, 2009
Table 5.52 Potential Indications for Alimta, 2009
Table 5.53 Alimta World Sales, 2005-2009
Table 5.54 Alimta World Sales Forecast, 2010-2025
Table 5.55 SWOT Analysis for Alimta, 2010
Table 6.1 The Top Five Oncology Companies: Relevant World Sales, 2009
Table 6.2 Roche’s Oncology Revenue, 2009
Table 6.3 Key Products in Roche’s Oncology Portfolio: World Sales, 2009
Table 6.4 Roche’s Oncology Pipeline, 2009
Table 6.5 Novartis’ Oncology Revenue, 2009
Table 6.6 Key Products in Novartis’ Oncology Portfolio: World Sales, 2009
Table 6.7 Novartis’ Oncology Pipeline, 2009
Table 6.8 Sanofi-Aventis’ Oncology Revenue, 2009
Table 6.9 Key Products in Sanofi-Aventis’ Oncology Portfolio: World Sales, 2009
Table 6.10 Sanofi-Aventis’ Oncology Pipeline, 2009
Table 6.11 AstraZeneca’s Oncology Revenue, 2009
Table 6.12 Key Products in AstraZeneca’s Oncology Portfolio: World Sales, 2009
Table 6.13 AstraZeneca’s Oncology Pipeline, 2009
Table 6.14 Eli Lilly’s Oncology Revenue, 2009
Table 6.15 Key Products in Eli Lilly’s Oncology Portfolio: World Sales, 2009
Table 6.16 Eli Lilly’s Oncology Pipeline, 2009
Table 7.1 SWOT Analysis of the Global Anti-Cancer Drugs Market, 2010-2025
Table 7.2 The Importance of Personalised Medicine in Oncology
Table 7.3 Disadvantages of Intravenous Chemotherapy
Table 7.4 Disadvantages of Oral Administration
Table 7.5 How the NCI Allocated its Cancer Research Budget in 2008
Table 7.6 Estimated GDP per Capita for BRICT and the US, 2010-2025
List of Figures
Figure 2.1 Global Cancer Incidence and Mortality, 2010-2025
Figure 2.2 The Ten Most Common Cancers by Incidence, 2008
Figure 2.3 Five-Year Survival Rates of Nine Cancers in the UK
Figure 4.1 Oncology Drug Sales by Region, 2009
Figure 4.2 Oncology Market Shares of the Seven Major Markets and Five Emerging Markets, 2009
Figure 4.3 Comparison of the Oncology Revenues of the US, Six Other Leading Markets and Five Emerging Market Groups, 2009
Figure 4.4 The Seven Leading National Markets: Market Shares, 2009
Figure 4.5 The Five Emerging Markets: Market Shares, 2009
Figure 4.6 Oncology Market by Therapy Type: Market Shares, 2009
Figure 4.7 Oncology Drug Market: World Sales Forecasts, 2010-2025
Figure 4.8 Traditional Antineoplastics: World Sales and Market Shares, 2009
Figure 4.9 Traditional Antineoplastics Market: World Sales Forecast, 2010-2025
Figure 4.10 Novel Antineoplastics Market Categories: Market Shares, 2009
Figure 4.11 Novel Antineoplastics Market: World Sales Forecast, 2010-2025
Figure 4.12 Hormone Therapy Subtypes: World Sales and Market Shares, 2009
Figure 4.13 Hormone Therapy Market: World Sales Forecast, 2010-2025
Figure 4.14 Immunotherapy Subtypes: Market Shares, 2009
Figure 4.15 Immunotherapy Market: World Sales Forecast, 2010-2025
Figure 4.16 Overall Categories: Market Shares, 2010-2025
Figure 5.1 Top Ten Drugs by Category and Subcategory, 2009
Figure 5.2 Costs of the Top Ten Anti-Cancer Drugs in the UK, 2009
Figure 5.3 Avastin World Sales Forecast, 2010-2025
Figure 5.4 MabThera World Sales Forecast, 2010-2025
Figure 5.5 Herceptin World Sales Forecast, 2010-2025
Figure 5.6 Glivec/Gleevec World Sales Forecast, 2010-2025
Figure 5.7 Taxotere World Sales Forecast, 2010-2025
Figure 5.8 Eloxatin World Sales Forecast, 2010-2025
Figure 5.9 Arimidex World Sales Forecast, 2010-2025
Figure 5.10 Gemzar World Sales Forecast, 2010-2025
Figure 5.11 Marketing of Erbitux: Revenue Split, 2009
Figure 5.12 Erbitux World Sales Forecast, 2010-2025
Figure 5.13 Alimta World Sales Forecast, 2010-2025
Figure 6.1 Top Five Companies: Relevant Market Shares, 2009
Figure 6.2 How Oncology Products Contributed to Roche’s Pharmaceutical Revenue, 2009
Figure 6.3 Key Products in Roche’s Oncology Portfolio by Share of Oncology Revenue, 2009
Figure 6.4 How Oncology Products Contributed to Novartis’ Pharmaceutical Revenue, 2009
Figure 6.5 Key Products Novartis’ Oncology Portfolio by Share of Oncology Revenues, 2009
Figure 6.6 How Oncology Products Contributed to Sanofi-Aventis’ Pharmaceutical Revenue, 2009
Figure 6.7 Key Products in Sanofi-Aventis’ Oncology Portfolio by Share of Oncology Revenue, 2009
Figure 6.8 How Oncology Products Contributed to AstraZeneca’s Pharmaceutical Revenue, 2009
Figure 6.9 Key Products in AstraZeneca’s Oncology Portfolio by Share of Oncology Revenue, 2009
Figure 6.10 How Oncology Products Contributed to Eli Lilly’s Pharmaceutical Revenue, 2009
Figure 6.11 Key Products in Eli Lilly’s Oncology Portfolio by Share of Oncology Revenue, 2009
Figure 7.1 NCI Research Spend, Incidence and Mortality for Different Cancers